Antiviral therapy is not enough to prevent hepatocellular carcinoma development in patients with chronic hepatitis B.
نویسنده
چکیده
The study of Cho et al. (1) will be published in one of the upcoming issue of Gut. They compared the risk of hepatocellular carcinoma among patients with inactive HBsAg carriers (1014 patients) and antiviral initiated naive chronic active hepatitis (757 HBeAg positive and 621 HBeAg negative patients). Mean follow-up period was 42 months for both groups. Among the antiviral using group the incidence of HCC development was 7.7% (106 patients), whereas it was 1.1% (11 patients) for inactive HBsAg carriers.
منابع مشابه
Antiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma: Indications and Prognosis.
BACKGROUND Chronic hepatitis B and C infections represent major risk factors for the development of hepatocellular carcinoma (HCC). Recently, the management of patients with viral hepatitis has dramatically changed. In the present review we discuss the impact of these developments on the prevention of HCC as well as the treatment of patients with HCC. METHODS Studies indexed in Medline betwee...
متن کاملRole of antiviral therapy in patients with chronic hepatitis B or C virus in preventing the development of hepatocellular carcinoma
Patients with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection are at significant risk for hepatocellular carcinoma (HCC). The most important risk factor associated with HCC is liver cirrhosis, which is again predominantly caused by chronic HBV or HCV infection. The most effective approach to avoid HCC development is to prevent HBV and HCV infection through vaccination. Ind...
متن کاملThe role of oral antiviral therapy in hepatitis B-related hepatocellular carcinoma
Hepatitis B virus (HBV) is the leading cause of hepatocellular carcinoma (HCC) in places where chronic hepatitis B infection is endemic. Oral nucleos(t)ide analog (NA) therapy can reduce the risk of HCC, but cannot completely prevent its development. For HBV-related HCCs, viral inhibition by NAs can preserve or improve liver function, thereby increasing the chance of therapeutic intervention. A...
متن کاملDoes antiviral therapy prevent hepatocellular carcinoma?
Chronic infection with HBV or HCV can lead to the development of hepatocellular carcinoma (HCC). The major risk factors for HBV-related HCC are persistent presence of hepatitis B e antigen (HBeAg) and/or high serum HBV DNA levels, and cirrhosis. The major risk factor for HCV-related HCC is cirrhosis. One randomized double blind controlled trial of lamivudine in patients with HBeAg and/or high s...
متن کاملFrequency of YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines
Abstract Background: Investigators were suspicious of tyrosine-methionine-aspartate-aspartate (YMDD) mutations occurred only in patients who were treated by lamivudine. However, YMDD mutations of hepatitis B virus gene (HBV DNA) in patients with chronic hepatitis B (CHB) untreated with antiviral medicines was reported in some studies. The aim of this study was to evaluate YMDD mutations in Ira...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
دوره 25 1 شماره
صفحات -
تاریخ انتشار 2014